Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
AI Overview
This RFP seeks development of small-molecule antifungal compounds effective against resistant fungi like Candida auris and Aspergillus species. The goal is to address rising fungal infection rates and hospitalizations by creating safer, broad-spectrum alternatives to current treatments limited by toxicity and drug resistance.
This summary is AI-generated from the official solicitation.
Key Details
Official Description
Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals. Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector. Fungal wound infections in...
More Department of Defense Opportunities
Get Alerts for Opportunities Like This
RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.
Start Free Trial